SCHEMBL716068

SCHEMBL716068

Cc1nn(-c2ccccc2Cl)cc1C(O)C1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 5/20 0.41
TDO2 P48775 4/20 0.41
NOTUM Q6P988 1/20 0.36
PARP1 P09874 1/20 0.34
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2D6 P10635 2/20 0.34
CYP1A2 P05177 1/20 0.34
GLA P06280 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
KMT2A Q03164 1/20 0.34
CYP2B6 P20813 1/20 0.34
OPRM1 P35372 1/20 0.33
HTT P42858 1/20 0.33
CNR1 P21554 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718900 0.83 ALDH1A1 (0.37) IDO1NPSR1MEN1KMT2AHTT
SCHEMBL720433 0.82 P2RX7 (0.41) IDO1TDO2GLANPSR1MEN1
SCHEMBL716678 0.80 IDO1 (0.40) IDO1TDO2NOTUMCNR1ADORA3
SCHEMBL718429 0.79 PKM (0.41) IDO1TDO2NOTUMPARP1MEN1
SCHEMBL717249 0.76 HDAC9 (0.36) IDO1TDO2KMT2ACNR1
SCHEMBL717194 0.74 CYP19A1 (0.43) IDO1TDO2MEN1KMT2ACNR1
SCHEMBL717876 0.73 IDO1 (0.38) IDO1TDO2CYP3A4CYP1A2CYP2C19
SCHEMBL720503 0.73 IDO1 (0.42) IDO1TDO2NPSR1MEN1KMT2A
SCHEMBL717877 0.73 BCHE (0.42) NOTUMCYP3A4CYP1A2CYP2C19HTT
SCHEMBL720156 0.72 IDO1 (0.38) IDO1TDO2KMT2AADORA3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP IDO1 2682/4885TDO2 3922/4885NOTUM 1954/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP IDO1 2682/4885TDO2 3922/4885NOTUM 1954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.